Výsledky vyhledávání - "Alberto San Juan del Moral"

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group)

Autor: Paula Jiménez-Fonseca, Oscar Alfredo Castillo Trujillo, Federico Longo, Mercedes Rodríguez Garrote, Alfredo Carrato, Juan José Serrano Domingo, Jaime Portela, Alberto San Juan del Moral, Enrique Aranda, Juana María Cano, Pablo Reguera Puertas, Elena Corral de la Fuente, Marta Izquierdo Manuel, Roberto Martin Huertas

Publikováno v: Journal of Clinical Oncology. 37:e15707-e15707

e15707 Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a five-year overall survival (OS) of less than 5%. Folfirinox and Nab-Paclitaxel plus Gemcitabine (NabPacGem) are the most active treatments in the fi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::70d06884807919271f875dfd83f2eac5
https://doi.org/10.1200/jco.2019.37.15_suppl.e15707

Zobrazit plný text záznamu

Head and neck cancer in the elderly: Survival and toxicity with biochemoradiation therapy

Autor: Ismael Ghanem, Hernán Cortés-Funes, Juan A. Núñez, Beatriz Castelo, Asuncion Diaz Serrano, Ruth Alvarez, Andrés Redondo, Silvia Garcia Adrian, Alberto San Juan del Moral, Lara Iglesias

Publikováno v: Journal of Clinical Oncology. 32:e17054-e17054

e17054 Background: There is an increasing number of older patients diagnosed of locally advanced head and neck cancer (LA-HNC) due to the growing life expectancy. The aim of this study is to assess the suitability of bio-chemoradiation therapy (BCRT)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3223b6c58505a02cb501042f9929cbc
https://doi.org/10.1200/jco.2014.32.15_suppl.e17054

Zobrazit plný text záznamu

Docetaxel-carboplatin-bevacizumab (TCV): A novel combination that promises a high activity in triple-negative breast cancer: A pilot study

Autor: Ana Rosa Rubio Salvador, Laura Diaz Paniagua, Jose Ignacio Chacon, Miguel Angel Cruz Mora, Lourdes Fernandez Franco, Sonia Alonso Soler, Carmen Esteban, Begona Martinez Carrasco, Nazaret Cordero Franco, Paloma Moya Gomez, Alberto San Juan del Moral

Publikováno v: Web of Science

e11543 Background: Triple negative breast cancer (TNBC) is an anthracycline resistant subtype, for which there is no standard chemotherapy. Taxanes, platinum-derived drugs and bevacizumab all seem to be active drugs in this setting, but definitive da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c10dddebabc5a744581463207d44a3
https://doi.org/10.1200/jco.2012.30.15_suppl.e11543

Zobrazit plný text záznamu

Would warning of osteonecrosis of the jaw (ONJ) have induced a change in the administration schedule of zoledronic acid (ZA)? A report from Toledo, Spain

Autor: Jose Ignacio Chacon, Carmen Esteban, Laura Diaz Paniagua, Alberto San Juan del Moral, Begona Martinez Carrasco, Miguel Angel Cruz Mora, Nazaret Cordero Franco, Sonia Alonso Soler, Enriqueta Munoz Platon, Ana Rosa Rubio Salvador, José Manuel Martínez Sesmero, Lourdes Fernandez Franco, Paloma Moya Gomez

Publikováno v: Web of Science

e19596 Background: ZA therapy has been associated with the development of ONJ. In Nov 8th, 2005, osteonecrosis of the jaw was elevated to a safety warning by Spanish Drug Agency (SDA). The aim of this study was to investigate if that warning has had

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e8165659da5b1d9febe981c3dc165c3
https://publons.com/wos-op/publon/54862455/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání